Regulation - Ferring Pharmaceuticals

Filter

Current filters:

Ferring Pharmaceuticals

Popular Filters

UK NICE to hold oral appeal hearing for Ferring’s Firmagon

UK NICE to hold oral appeal hearing for Ferring’s Firmagon

18-06-2014

Privately-held Switzerland-headquartered drugmaker Ferring Pharmaceuticals confirmed today that its drug…

Ferring PharmaceuticalsFirmagonOncologyPharmaceuticalRegulationUK

NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

15-04-2014

In final draft guidance published today, the UK’s National Institute for Health and Care Excellence…

AnatomyCare ExcellenceFerring PharmaceuticalsFirmagonHealth Medical PharmaMedicineOncologyPharmaceuticalRegulationUKUnited Kingdom

UK NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

UK NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

27-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence has issued new draft guidance…

EuropeFerring PharmaceuticalsFirmagonOncologyPharmaceuticalPricingRegulationUK

Eisai and Toyama's iguratimod, and Astellas' Gonax OKed in Japan

03-07-2012

Japanese drug major Eisai (TYO: 4523) and Toyama Chemical have received approval from Japan's Ministry…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCareramdegarelixEisaiFerring PharmaceuticalsGonaxiguratimodKolbetOncologyPharmaceuticalRegulationToyama

Back to top